Press Releases

Amprion Exhibits at MDS International Congress of Parkinson’s Disease and Movement Disorders in Madrid and Presents Scientific Insights On SYNTap® Test at Prion2022 Conference

San Francisco Amprion, a leader in diagnostics for neurodegenerative diseases, invites researchers and practitioners attending MDS to visit Amprion at booth #212. We look forward

Amprion Announces Research Collaboration With Mayo Clinic To Further Understand Rapidly Progressive Dementia

Amprion is pleased to announce a research collaboration with Mayo Clinic in Florida to investigate biomarker utility within the cerebrospinal fluid (CSF) from patients with

Amprion Awarded NIH Grant For Analytical Validation of SYNTap® Biomarker Test For Neurological Disease

Thanks to additional research funding from NIH/NINDS, Amprion joins the world’s heightened focus during Alzheimer’s & Brain Health Awareness Month by expanding its quantitative study

SYNTap Biomarker Test helps doctors distinguish Parkinson’s from Parkinsonism in early stages

For the first time in history, Amprion’s breakthrough SYNTapÒ Biomarker Test can help doctors effectively distinguish Parkinson’s Disease (PD) from Parkinsonism early. This innovative test

Amprion Announces Commercial Rollout of the SYNTap Test at the AAN Annual Meeting and the Formation of Clinical Advisory Board

We invite AAN Annual Meeting attendees to visit Amprion’s booth #1074 and meet our CEO/Co-Founder and clinical director. Explore the science behind the SYNTapⓇ Biomarker

New Insights on Alzheimer’s and What it means for Personalized Medicine

A rapidly aging nation, the U.S. has 60 million people aged 65 and older. Of these, about 12 million people show early symptoms of Mild

Amprion Awarded CAP Accreditation

Amprion Clinical Laboratory Receives Accreditation From College Of American Pathologists San Francisco, CA / Oct. 27th, 2021—Amprion announces that The Accreditation Committee of the College

Launch of SYNTap™ Test

SYNTap™ Test Announcement Breakthrough biomarker test aids physicians in diagnosing synucleinopathies by detecting misfolded Synuclein aggregates in cerebrospinal fluid (CSF). Alpha-Synuclein is a misfolded protein

US FDA Awards Amprion Breakthrough Device Designation

For Immediate Release May 22, 2019 Amprion Joins the Fight Against Parkinson’s Through Early Detection Testing FDA Grants Breakthrough Device Designation For Amprion’s PMCA

A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.